Review on treatment of pleural metastasis and malignant pleural effusion with Pressurized IntraThoracic Aerosol Chemotherapy (PITAC)

Pleura and Peritoneum 2024 May 17 [Link] Pernille Schjødt Hansen, Martin Graversen, Sönke Detlefsen, Michael Bau Mortensen Abstract Background: Malignant pleural effusion (MPE) is a common and debilitating condition seen in advanced cancer disease, and life-expectancy is short. Symptoms include pain and severe shortness of breath. Current first-line treatment options include pleural drainage using catheters…

Read More

Leveraging the pleural space for anticancer therapies in pleural mesothelioma

The Lancet Respiratory Medicine 2024 May 10 [Link] Kevin G Blyth, Prasad S Adusumilli, Philippe Astoul, Liz Darlison, Y C Gary Lee, Aaron S Mansfield, Stefan J Marciniak, Nick Maskell, Vasiliki Panou, Tobias Peikert, Najib M Rahman, Marjorie G Zauderer, Daniel Sterman, Dean A Fennell Abstract Most patients with pleural mesothelioma (PM) present with symptomatic…

Read More

Successful treatment of simultaneous malignant pleural mesothelioma and pulmonary adenocarcinoma: A case report

Oncology Letters 2024 February 15 [Link] Yuki Amakusa, Tatsuro Suzuki, Yu Hikosaka, Masaya Takemura, Tetsuya Oguri Abstract The present report described the case of a 74-year-old male patient with asbestos exposure whose chest computed tomography revealed a right lower lobe nodule and right pleural effusion. Pleural biopsy led to the diagnosis of epithelial malignant pleural…

Read More

Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues

BMJ Case Reports 2024 February 10 [Link] Keiichi Mizuhashi, Kenzo Okamoto, Kazuki Nabeshima, Takumi Kishimoto Abstract Sarcomatoid mesothelioma is difficult to differentiate from other mesotheliomas. Here, we describe the case of a man in his early 80s with sarcomatoid mesothelioma and a history of asbestos exposure. He initially presented with right-sided chest pain and was…

Read More

Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma

Diagnostic Cytopathology 2024 January 20 [Link] Nazli Sena Şeker, Emel Tekin, Güntülü Ak, Muzaffer Metintaş, Selma Metintaş, Emine Dündar Abstract Background: Mesothelioma is a malignant neoplasm with a poor survival rate. We aimed to investigate the importance of BAP1, MTAP (IHC), and p16/CDKN2A homozygous deletion (FISH) in cytologic material obtained from pleural effusion sampling, which…

Read More

Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series

Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…

Read More

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers

Journal of Clinical Medicine 2023 November 9 [Link] Claudio Sorino, Michele Mondoni, Giampietro Marchetti, Sergio Agati, Riccardo Inchingolo, Federico Mei, Sara Flamini, Filippo Lococo, David Feller-Kopman Abstract Pleural mesothelioma (PM) is a type of cancer that is highly related to exposure to asbestos fibers. It shows aggressive behavior, and the current therapeutic approaches are usually…

Read More